MedXcel

Online Web Activities - Dev

CHOLECYSTOKININ-CHOLESCINTIGRAPHY (CCK-CS) IN CHRONIC ABDOMINAL PAIN: Basics and Standard Application State-of-the-Art Review

To participate in this on-demand web program (valid thru June 1, 2024) Register Here

This program will provide guidance for clinicians who diagnose and treat biliary pain and functional gall bladder disorders and will use case studies to demonstrate how to appropriately apply CCK-CS to clinical decision making, including the decision to recommend cholecystectomy. For nuclear medicine physicians, pharmacists, and radiologic technologists.

CHOLECYSTOKININ-CHOLESCINTIGRAPHY (CCK-CS) IN CHRONIC ABDOMINAL PAIN: Case-Based Review of Practice Pearls

To participate in this on-demand web program (valid thru November 1, 2024) Register Here

This program will provide clinicians with the diagnostic precision of using (CCK-CS) in determining the pathology of chronic abdominal pain which requires a systematic approach and represents an unmet medical need. In this webinar, several case studies will be presented to demonstrate a systematic approach using a structured reporting checklist to ensure consistent detection of rare but consequential diagnoses. For nuclear medicine physicians, pharmacists, and radiologic technologists.

"Coronary Flow Capacity Assessment of Coronary Artery Physiology with Cardiac Positron Emission Tomography"

To participate in this on-demand web program (valid thru August 7, 2024) Register Here

The presentation will provide clarity concerning the tools to measure MBF and their interrelationship. The concept of coronary flow capacity (CFC) will be presented and its relevance and impact on clinical practice and patient care will be discussed. Clinicians who participate in this program will gain an appreciation for the use of positron emission tomography (PET) scanning with CFC to help identify patients who will benefit from revascularization. For nuclear medicine physicians, pharmacists, and radiologic technologists.

"Coronary Flow Capacity: HOW DOES IT DIFFER FROM CFR AND WHY IS IT BETTER FOR PATIENT MANAGEMENT?"

To participate in this on-demand web program (valid thru February 21, 2024) Register Here

This presentation will provide insight into the measurement of myocardial blood flow (MBF) and its interpretation. The presentation will provide clarity concerning various metrics of MBF, the relationship between the metrics and how these metrics may be discordant with each other and with angiographic findings. The concept of coronary flow capacity (CFC) will be presented and its relevance and impact on clinical practice and patient care will be discussed. Clinicians who participate in this program will gain an appreciation for the use of positron emission tomography (PET) scanning with CFC to help identify patients who will benefit from revascularization. For nuclear medicine physicians, pharmacists, and radiologic technologists.

"Why Does My Patient Have Angina?"

To participate in this on-demand web program (valid thru July 27, 2024) Register Here

Dr. Johnson will provide educational insight into a contemporary approach to the diagnosis and management of angina taking into consideration epicardial coronary disease, microcirculatory dysfunction, and coronary vasospasm. This insight will enhance physician appraisal of ischemic heart disease (IHD) through the consideration of all pathophysiology relevant to symptoms, prognosis and treatment and result in improved health outcomes for patients.

"We've Measured Flow. Now What Does It Mean?"

To participate in this on-demand web program (valid thru October 3, 2024) Register Here

This lecture will detail the scientific literature describing myocardial perfusion dating back to the first measurements in 1949. The goal is to synthesize the entire spectrum of myocardial perfusion in order to understand objective limits for distinguishing normal from abnormal. We first discuss myocardial perfusion in normal people (not patients!) aged less than 40 with no risk factors. From this cohort we can understand truly normal perfusion, not accessible or measured invasively due to unethical risk of invasive catheterization for people. At the other end of the spectrum, transmural or nontransmural infarcts as verified by cardiac magnetic resonance imaging permit a boundary of low resting flows identifies nonviable myocardium. Frank ischemia (angina, ST-segment depression, and a relative perfusion defect) and its associated myocardial perfusion can be imaged to understand how stress flows must fall in order to reach this low level. A wide continuum falls between normal flows and ischemia and relates to risk factor burden, anatomic atherosclerosis, clinical heart disease, and previous revascularization procedures.

"Clinical Confidence in MBF: How to Incorporate it with Certainty and Accuracy?"

To participate in this on-demand web program (valid thru April 11, 2024) Register Here

The top questions that come from cardiology practices about incorporating myocardial blood flow (MBF)/PET Flow into their diagnostic protocol will be presented and discussed by Dr. Nils Johnson. The questions will include scanner considerations, dosing protocols for MBF, confidence in the accuracy of MBF values, the value of MBF compared to FFR and FFRct and more. The goal is to provide data and information to enable informed decision-making by cardiology practices on how to incorporate PET Flow.

Note: a protype program was presented at the American Society of Nuclear Cardiology (ASNC) meeting on September 9, 2022 and was refined based on feedback from participants.

"A Current Perspective on Testing & Imaging for Cardiology Practice: SPECT vs CTA vs PET"

To participate in this on-demand web program (valid thru June 14, 2024) Register Here

There are an increasing number and type of cardiac tests used to help stratify patients at risk for coronary artery disease (CAD), specifically for complications such as myocardial infarction (MI) or sudden cardiac death. The debate surrounding testing and imaging in cardiology practice continues, including anatomical versus functional, invasive versus noninvasive, diagnostic accuracy. Single-photon computed tomography (SPECT), computed tomography angiography (CTA), and positron emission tomography (PET) are the focus of this debate. Dr. Nils Johnson will present published data and clinical experience to support the advantages and disadvantages of SPECT versus CTA versus PET. Among the discussion topics discussed are the differences in sensitivity, diagnostic accuracy, tracers, spatial resolution with ease of use and value.

"Post Ischemia Trial and Clinical Decision Making: The Clinical Fit for PET Flow"

To participate in this on-demand web program (valid thru November 20, 2024) Register Here

Expert faculty will review the data from the landmark ISCHEMIA Trial published in the New England Journal of Medicine in 2020. This $100 million Federally funded trial is the largest to date comparing an invasive strategy versus optimal medical therapy (OMT) in patients with stable coronary artery disease and moderate-to-severe ischemia on functional testing. Faculty presenter will discuss the findings of the ISCHEMIA Trial and their impact on clinical decision-making. He will also discuss the limitations and the strengths of the study and the ongoing challenges of not only figuring out whether invasive or conservative therapy is better, but also to identify those patients at the outset who will fail, and the need to identify newer, more effective treatments.